Intra-Cellular Therapies Statistics
Total Valuation
Realbotix has a market cap or net worth of 47.61 million. The enterprise value is 48.55 million.
| Market Cap | 47.61M |
| Enterprise Value | 48.55M |
Important Dates
The next estimated earnings date is Tuesday, August 19, 2025.
| Earnings Date | Aug 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Realbotix has 199.94 million shares outstanding. The number of shares has increased by 65.65% in one year.
| Current Share Class | 199.94M |
| Shares Outstanding | 199.94M |
| Shares Change (YoY) | +65.65% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 49.05% |
| Owned by Institutions (%) | 1.53% |
| Float | 101.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.86 |
| PB Ratio | 11.05 |
| P/TBV Ratio | 15.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.63 |
| EV / Sales | 20.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of 0.46.
| Current Ratio | 0.75 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.11 |
Financial Efficiency
Return on equity (ROE) is -187.76% and return on invested capital (ROIC) is -25.91%.
| Return on Equity (ROE) | -187.76% |
| Return on Assets (ROA) | -24.06% |
| Return on Invested Capital (ROIC) | -25.91% |
| Return on Capital Employed (ROCE) | -79.51% |
| Revenue Per Employee | 104,198 |
| Profits Per Employee | -802,505 |
| Employee Count | 23 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -399,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +104.03% in the last 52 weeks. The beta is 2.91, so Realbotix's price volatility has been higher than the market average.
| Beta (5Y) | 2.91 |
| 52-Week Price Change | +104.03% |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | 0.23 |
| Relative Strength Index (RSI) | 32.10 |
| Average Volume (20 Days) | 180,154 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.22 |
Income Statement
In the last 12 months, Realbotix had revenue of 2.40 million and -18.46 million in losses. Loss per share was -0.10.
| Revenue | 2.40M |
| Gross Profit | -155,693 |
| Operating Income | -4.42M |
| Pretax Income | -18.41M |
| Net Income | -18.46M |
| EBITDA | n/a |
| EBIT | -4.42M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 991,713 in cash and 1.99 million in debt, giving a net cash position of -994,501 or -0.00 per share.
| Cash & Cash Equivalents | 991,713 |
| Total Debt | 1.99M |
| Net Cash | -994,501 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 4.31M |
| Book Value Per Share | 0.02 |
| Working Capital | -499,906 |
Cash Flow
| Operating Cash Flow | -5.31M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -6.50% |
| Operating Margin | -184.26% |
| Pretax Margin | -768.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -184.26% |
| FCF Margin | n/a |
Dividends & Yields
Realbotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -65.65% |
| Shareholder Yield | n/a |
| Earnings Yield | -38.77% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 30, 2021. It was a reverse split with a ratio of 0.0882924.
| Last Split Date | Apr 30, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.0882924 |
Scores
Realbotix has an Altman Z-Score of -2.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.25 |
| Piotroski F-Score | 2 |